X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2018 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare Aventis Pharma with Fulford India - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

SANOFI INDIA vs FULFORD INDIA - Comparison Results

SANOFI INDIA    Change

Sanofi India (the erstwhile Aventis Pharma), the 60% subsidiary of Sanofi-Aventis SA, France, is one of the largest pharma MNCs in India with a turnover of over Rs 13.2 bn in CY11. Domestic sales constituted 81% of total sales in CY11 and exports con... More

FULFORD INDIA 
   Change

Fulford (India) Limited is an Indian affiliate of Schering-Plough Corporation, USA. The company has presence in oncology, virology and cardiovascular segments. In FY06 the topline of the company grew by 15.5% to Rs. 1519 m from Rs. 1279 m in FY05. PA... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    SANOFI INDIA FULFORD INDIA SANOFI INDIA/
FULFORD INDIA
 
P/E (TTM) x 38.9 398.8 9.8% View Chart
P/BV x 8.4 6.2 135.0% View Chart
Dividend Yield % 1.1 0.1 1,269.7%  

Financials

 SANOFI INDIA   FULFORD INDIA
EQUITY SHARE DATA
    SANOFI INDIA
Dec-16
FULFORD INDIA
Mar-14
SANOFI INDIA/
FULFORD INDIA
5-Yr Chart
Click to enlarge
High Rs4,560942 484.1%   
Low Rs4,400450 977.8%   
Sales per share (Unadj.) Rs1,028.5691.4 148.8%  
Earnings per share (Unadj.) Rs129.011.5 1,125.2%  
Cash flow per share (Unadj.) Rs186.015.4 1,210.9%  
Dividends per share (Unadj.) Rs68.002.00 3,400.0%  
Dividend yield (eoy) %1.50.3 528.2%  
Book value per share (Unadj.) Rs753.6380.0 198.3%  
Shares outstanding (eoy) m23.033.90 590.5%   
Bonus/Rights/Conversions ---  
Price / Sales ratio x4.41.0 432.7%   
Avg P/E ratio x34.760.7 57.2%  
P/CF ratio (eoy) x24.145.3 53.2%  
Price / Book Value ratio x5.91.8 324.6%  
Dividend payout %52.717.4 302.2%   
Avg Mkt Cap Rs m103,1742,714 3,801.0%   
No. of employees `0003.60.4 816.0%   
Total wages/salary Rs m3,592505 711.3%   
Avg. sales/employee Rs Th6,537.76,073.0 107.7%   
Avg. wages/employee Rs Th991.41,137.4 87.2%   
Avg. net profit/employee Rs Th819.8100.7 814.3%   
INCOME DATA
Net Sales Rs m23,6862,696 878.4%  
Other income Rs m708125 564.6%   
Total revenues Rs m24,3942,822 864.5%   
Gross profit Rs m5,281-46 -11,381.5%  
Depreciation Rs m1,31315 8,638.2%   
Interest Rs m1510 157.9%   
Profit before tax Rs m4,66154 8,583.8%   
Minority Interest Rs m00-   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m00-   
Tax Rs m1,69110 17,614.6%   
Profit after tax Rs m2,97045 6,644.3%  
Gross profit margin %22.3-1.7 -1,295.7%  
Effective tax rate %36.317.7 205.2%   
Net profit margin %12.51.7 756.4%  
BALANCE SHEET DATA
Current assets Rs m15,6731,738 901.6%   
Current liabilities Rs m6,678545 1,226.0%   
Net working cap to sales %38.044.3 85.8%  
Current ratio x2.33.2 73.5%  
Inventory Days Days7648 156.8%  
Debtors Days Days224 518.4%  
Net fixed assets Rs m8,09812 68,050.4%   
Share capital Rs m23039 590.5%   
"Free" reserves Rs m17,0881,443 1,184.2%   
Net worth Rs m17,3561,482 1,171.1%   
Long term debt Rs m00-   
Total assets Rs m25,4002,077 1,223.1%  
Interest coverage x311.76.7 4,641.8%   
Debt to equity ratio x00-  
Sales to assets ratio x0.91.3 71.8%   
Return on assets %11.82.6 450.3%  
Return on equity %17.13.0 567.3%  
Return on capital %26.94.3 625.8%  
Exports to sales %24.50-   
Imports to sales %28.024.5 114.4%   
Exports (fob) Rs m5,801NA-   
Imports (cif) Rs m6,627659 1,005.2%   
Fx inflow Rs m7,14517 41,540.7%   
Fx outflow Rs m6,846673 1,017.0%   
Net fx Rs m299-656 -45.6%   
CASH FLOW
From Operations Rs m3,22690 3,584.4%  
From Investments Rs m-1,555105 -1,486.6%  
From Financial Activity Rs m-1,818-14 12,893.6%  
Net Cashflow Rs m-147181 -81.4%  

Share Holding

Indian Promoters % 0.0 0.0 -  
Foreign collaborators % 60.4 75.0 80.5%  
Indian inst/Mut Fund % 14.4 3.8 378.9%  
FIIs % 14.6 0.1 14,600.0%  
ADR/GDR % 0.0 0.0 -  
Free float % 10.5 21.2 49.5%  
Shareholders   15,184 4,783 317.5%  
Pledged promoter(s) holding % 0.0 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare SANOFI INDIA With:   MERCK LTD  CIPLA  ASTRAZENECA PHARMA  VENUS REMEDIES  STERLING BIOTECH  

Compare SANOFI INDIA With:   ADCOCK INGRAM (S. Africa)  MYLAN (US)  ACTAVIS (US)  TEVA PHARMA (Israel)  



Today's Market

Sensex Ends 170 Points Lower, Realty and FMCG Stocks Witness Selling(Closing)

After opening the day on a positive note, share markets in India witnessed volatile trading activity and ended in red.

Related Views on News

BIOCON LTD at All Time High; BSE HEALTHCARE Index Up 0.7% (Market Updates)

Sep 19, 2018 | Updated on Sep 19, 2018

BIOCON LTD share price has hit an all time high at Rs 695 (up 1.6%). The BSE HEALTHCARE Index is up by 0.7%. Among the top gainers in the BSE HEALTHCARE Index today are BIOCON LTD (up 1.6%) and SANOFI INDIA (up 0.4%). The top losers include PIRAMAL ENTERPRISES and LUPIN LTD (down 0.1%).

DIVIS LABORATORIES at All Time High; BSE HEALTHCARE Index Up 1.2% (Market Updates)

Sep 19, 2018 | Updated on Sep 19, 2018

DIVIS LABORATORIES share price has hit an all time high at Rs 1,406 (up 1.8%). The BSE HEALTHCARE Index is up by 1.2%. Among the top gainers in the BSE HEALTHCARE Index today are DIVIS LABORATORIES (up 1.8%) and SANOFI INDIA (up 0.4%). The top losers include ABBOTT INDIA (down 0.1%) and ALEMBIC PHARMA (down 0.2%).

Aster DM Healthcare (IPO)

Feb 10, 2018

Should you subscribe to the IPO of Aster DM Healthcare Ltd?

Dr Reddy's: Milestone Payment Drives Sales (Quarterly Results Update - Detailed)

Feb 9, 2018

US business was hit by pricing pressure although there was growth sequentially led by new product launches.

Lupin: US market Declines Due to Higher Base Effect of FY17 (Quarterly Results Update - Detailed)

Feb 9, 2018

Price erosion in generic US drugs continues but seems to be bottoming out.

More Views on News

Most Popular

In a Crisis, if Petrol Prices Hit Rs 100, This Stock Could Be a Good Buy(The 5 Minute Wrapup)

Sep 6, 2018

The rise in the crude oil price is a major reason for the fall in the market. If crude oil prices keep on rising, what will happen to stocks?

Want Bigger Returns Than You Thought Possible? This is Where You Should Look(Profit Hunter)

Sep 12, 2018

Richa has discovered the single most profitable opportunity in the market - read on to discover more...

The Secret Of Mirae Asset India Equity Fund's Increasing Popularity(Outside View)

Sep 7, 2018

The prudent investment strategies followed at the fund house has helped Mirae Asset India Equity Fund earn a tag of being a consistent performer, which is in turn gaining popularity among investors.

Hurricanes Threaten Oil Spike, but the Saudis are Selling...(Vivek Kaul's Diary)

Sep 6, 2018

Oil prices are rising and could go even more higher amid rising tensions in Middle East.

Should You Be Worried About the Rising Dollar?(Chart Of The Day)

Sep 7, 2018

While the rupee has deprecated by about 5% annually since 1990 against the dollar, the BSE Sensex has returned 14% annually in the same period.

More

Small Investments
BIG Returns

Zero To Millions Guide 2018
Get our special report, Zero To Millions
(2018 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

SANOFI INDIA SHARE PRICE


Sep 19, 2018 (Close)

TRACK SANOFI INDIA

  • Track your investment in SANOFI INDIA with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

SANOFI INDIA 5-YR ANALYSIS

COMPARE SANOFI INDIA WITH

MARKET STATS